



Official reprint from UpToDate®

www.uptodate.com © 2022 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Wolters Kluwer

Acute simple cystitis in women

Authors: Thomas M Hooton, MD, Kalpana Gupta, MD, MPH**Section Editor:** Stephen B Calderwood, MD**Deputy Editor:** Allyson Bloom, MD

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: Jan 2022. | **This topic last updated:** Mar 15, 2021.

Please read the [Disclaimer](#) at the end of this page.

INTRODUCTION

Urinary tract infections (UTIs) include cystitis (infection of the bladder/lower urinary tract) and pyelonephritis (infection of the kidney/upper urinary tract). In women, the pathogenesis of UTIs begins with colonization of the vaginal introitus by uropathogens from the fecal flora, followed by ascension via the urethra into the bladder and, in the case of pyelonephritis, to the kidneys via the ureters.

This topic will review the approach to women with typical symptoms of cystitis when there is no concern that the infection has extended beyond the bladder. We consider this to be acute simple cystitis.

When there is concern that the infection has possibly extended beyond the bladder (eg, when there is flank pain or other features suggestive of pyelonephritis, fever, and/or other signs of systemic illness, including sepsis) we consider this to be a complicated UTI. This approach to categorizing UTI ([table 1](#)) differs from other conventions, as discussed in detail below.

Our approach to the diagnosis and management of complicated UTI is discussed elsewhere.

(See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults".](#))

Additionally, acute simple cystitis in men and UTIs in special populations are discussed elsewhere:

- (See ["Acute simple cystitis in men".](#))
- (See ["Urinary tract infections and asymptomatic bacteriuria in pregnancy".](#))
- (See ["Catheter-associated urinary tract infection in adults".](#))
- (See ["Kidney transplantation in adults: Urinary tract infection in kidney transplant recipients".](#))
- (See ["Recurrent simple cystitis in women".](#))

Asymptomatic bacteriuria is also discussed in detail elsewhere. (See ["Asymptomatic bacteriuria in adults".](#))

Urinary tract infection in children is also discussed separately. (See ["Urinary tract infections in children: Epidemiology and risk factors"](#) and ["Urinary tract infections in children: Long-term management and prevention"](#) and ["Urinary tract infections in infants and children older than one month: Clinical features and diagnosis"](#) and ["Urinary tract infections in infants older than one month and young children: Acute management, imaging, and prognosis".](#))

TERMINOLOGY

We use the term acute simple cystitis to refer to an acute urinary tract infection (UTI) that is presumed to be confined to the bladder ([table 1](#)). Such infections **lack** signs or symptoms that suggest an infection extending beyond the bladder, which include:

- Fever ($>99.9^{\circ}\text{F}/37.7^{\circ}\text{C}$) – This temperature threshold is not well defined and should be individualized, taking into account baseline temperature, other potential contributors to an elevated temperature, and the risk of poor outcomes should empiric antimicrobial therapy be inappropriate.
- Other signs or symptoms of systemic illness (including chills or rigors, significant fatigue or malaise beyond baseline).
- Flank pain.

- Costovertebral angle tenderness.

If any of these signs or symptoms are present in the setting of pyuria and bacteriuria, we consider the patient to have acute complicated UTI and manage the patient differently. By this definition, pyelonephritis is a complicated UTI, regardless of patient characteristics. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults"](#).)

We do not automatically consider patients with underlying urologic abnormalities (such as nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (such as neutropenia or advanced HIV infection), or poorly controlled diabetes mellitus to have a complicated UTI if they have no concerning symptoms for upper tract or systemic infection. However, such patients can be at higher risk for more serious infection and have not traditionally been included in studies evaluating the antibiotic regimens we typically use for acute simple cystitis. Thus, we follow such patients more closely and/or have a low threshold to manage them as complicated UTI (eg, if they have subtle signs or symptoms that could be suggestive of more extensive infection). Many patients with significant urologic abnormalities come to clinical attention for UTI because of signs or symptoms consistent with complicated UTI as defined here (rather than features of simple cystitis alone).

Certain populations, such as pregnant women and renal transplant recipients, have unique management considerations and thus are not included in the above categorization. These populations are discussed elsewhere. (See ["Urinary tract infections and asymptomatic bacteriuria in pregnancy"](#) and ["Kidney transplantation in adults: Urinary tract infection in kidney transplant recipients"](#).)

These definitions of acute simple cystitis and complicated UTI are different from other categorizations, which themselves are somewhat variable. Specifically, cystitis or pyelonephritis in a nonpregnant premenopausal woman without underlying urologic abnormalities has traditionally been termed acute uncomplicated UTI [1], and complicated UTI has been defined, for the purposes of treatment trials, as cystitis or pyelonephritis in a patient with underlying urologic abnormalities. Individuals who do not fit into either category have often been treated as having a complicated UTI by default. Rather than use this convention, we favor an approach to treatment based on the presumed extent of infection and severity of illness. Since complicated UTI, as defined here, is a more serious

infection than simple cystitis, the efficacy of an antimicrobial agent is of greater importance, and certain agents used for simple cystitis should not be used for complicated UTI because they do not achieve adequate levels in tissue, which may be important for cure. Risk for infection with drug-resistant organisms is a consideration in antibiotic selection for both simple cystitis and acute complicated UTI.

Women categorized as having acute uncomplicated cystitis according to the traditional definition would fall under the definition of acute simple cystitis that we use here.

EPIDEMIOLOGY

Cystitis among women is extremely common [2,3]. The shorter distance from the anus to the urethra likely explains why women are at higher risk for urinary tract infections (UTIs) than men.

Among otherwise healthy women, risk factors for cystitis include recent sexual intercourse and a history of UTI [4,5]. Use of spermicide-coated condoms, diaphragms, and spermicides alone are also associated with an increased cystitis risk.

Other comorbidities, such as diabetes mellitus and structural or functional urinary tract abnormalities, can also increase the risk of cystitis [2]. Although patients with these comorbidities have traditionally been categorized as having complicated UTI, our approach does not necessarily categorize them as such.

MICROBIOLOGY

Microbial spectrum — *Escherichia coli* is the most frequent microbial cause of simple cystitis (75 to 95 percent of cases), with occasional infections caused by other species of Enterobacteriaceae (such as *Klebsiella pneumoniae* and *Proteus mirabilis*) and other bacteria, such as *Staphylococcus saprophyticus* [6,7]. Other gram-negative and gram-positive species are infrequently isolated in acute simple cystitis in the absence of antimicrobial or health care exposures.

The microbial spectrum of simple cystitis in patients with recent antimicrobial or other health care exposures may be broader and also includes other gram-negative bacilli (eg, *Pseudomonas*), enterococci, and staphylococci. Thus, culture and susceptibility testing are essential for management in patients who have such risk factors ([table 2](#)). Even in the absence of specific risk factors, resistance in *E. coli* can be a major issue.

Among otherwise healthy nonpregnant women, the isolation of organisms such as lactobacilli, enterococci, Group B streptococci, and coagulase-negative staphylococci other than *S. saprophyticus* from voided midstream urine most commonly represents contamination of the urine specimen [8,9]. Nevertheless, it may be appropriate to consider these organisms the likely causative agent in symptomatic women when found in voided midstream urine at high counts and with pure growth (ie, without growth of other bacteria). That such organisms are rarely the cause of acute simple cystitis in such women is supported by a study of 202 premenopausal, nonpregnant women with acute cystitis who collected a midstream, clean-catch urine, and subsequently underwent urethral catheterization to collect a bladder urine specimen [10]. There was high concordance between growth on voided and catheterized specimens for *E. coli* (even at counts as low as 10 colony-forming units [CFU]/mL), *K. pneumoniae*, and *S. saprophyticus*. In contrast, enterococci and Group B streptococci were isolated from 20 and 25 voided specimens, respectively, but only from two corresponding catheterized specimens each. In the majority of specimens with these organisms, growth was $<10^4$ CFU/mL, and *E. coli* was also isolated.

Resistance trends in *E. coli* — Expected susceptibility patterns of *E. coli* should inform the empiric antimicrobial selection for cystitis. Increasing rates of resistance have been reported globally. Risk factors for urinary tract infection (UTI) with resistant organisms include recent broad-spectrum antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant organisms are prevalent [11-15] ([table 2](#)). Ongoing monitoring of local prevalence of resistance is necessary for optimization of empiric therapy. (See '[Empiric antimicrobial selection](#)' below.)

The in vitro susceptibility of *E. coli* varies considerably by geographic region. In four large studies, overall resistance rates were higher in medical centers in the United States than in Canada, and higher in Portugal and Spain than in other European countries [16-19]. In general, resistance rates >20 percent were reported in all regions for [ampicillin](#) and in many

regions for [trimethoprim](#) (with or without sulfamethoxazole).

[Nitrofurantoin](#), [fosfomycin](#), and [pivmecillinam](#) (the last is not available in the United States) have demonstrated good in vitro activity in all countries investigated [16-19] and are thus appropriate first-line agents for acute simple cystitis when there are no clear risk factors for resistance [1].

Resistance rates for first and second generation oral cephalosporins and amoxicillin-clavulanic acid are regionally variable but generally <10 percent.

Fluoroquinolone resistance rates have been <10 percent in most parts of North America and Europe, but there has been a clear trend of increasing resistance over time [16-21]. In a study of *E. coli* urinary isolates from outpatients in the United States, resistance rates to [ciprofloxacin](#) increased from 3 to 17 percent between 2000 and 2010 [20]. In a population-based study of over 5000 *E. coli* urinary isolates collected in Minnesota between 2005 and 2009, the incidence of urinary isolates resistant to fluoroquinolones and/or [trimethoprim-sulfamethoxazole](#) (TMP-SMX) increased among older adult patients and those with community-associated isolates, but not among health care-associated cases [21]. One caveat in interpreting these data is that passive laboratory-based surveillance methods tend to overestimate true resistance rates since they are skewed by urine cultures obtained from patients who may have failed initial therapy or who have specific risk factors for resistance, such as recent travel or antimicrobial use [22-24].

TMP-SMX is the agent for which there are the most data to guide clinical use; identified risk factors for resistance in women with acute simple cystitis include use of TMP-SMX in the preceding three to six months and travel, particularly international travel [25-28]. In addition, clinical, in vitro, and mathematical modeling studies have suggested that a 20 percent resistance prevalence should be the threshold at which TMP-SMX should not be used for empiric treatment of acute simple cystitis [29,30].

For other antimicrobial agents, there are insufficient data to determine the resistance levels at which the likelihood of failure outweighs the potential benefits; the decision depends on individual practitioner discretion. In addition, it is important for clinicians to understand that local resistance rates reported in hospital antibiograms are often skewed by cultures of

samples obtained from hospitalized patients or those with complicated infection and may not accurately predict susceptibilities in women with acute simple community-acquired cystitis, in whom resistance rates tend to be lower [31,32].

Nevertheless, resistant infections are increasing in number, including those caused by extended-spectrum beta-lactamase (ESBL)-producing strains. An increase in ESBL-producing isolates has been described among patients with acute simple cystitis worldwide [33-35]. In particular, a specific strain of *E. coli*, sequence type 131 (ST131), has emerged globally as a major cause of fluoroquinolone-resistant and ESBL-producing *E. coli* UTIs [36].

CLINICAL MANIFESTATIONS

The classic clinical manifestations of cystitis consist of dysuria, urinary frequency, urinary urgency, and suprapubic pain [37]. Hematuria is also often observed.

Symptoms of cystitis can occasionally be subtle and more difficult to tease out, particularly in older women. Older women can have a number of nonspecific urinary symptoms (such as chronic dysuria or urinary incontinence) that mimic symptoms of cystitis, even when there is no evidence of urinary tract infection (UTI). A systematic review of studies evaluating the diagnosis of UTI among community-dwelling adults older than 65 years suggested that symptoms such as chronic urinary nocturia, incontinence, and general sense of lack of well-being were common and nonspecific for UTI [38]. In contrast, acute dysuria (less than one week duration), new or worsening urinary urgency, new incontinence, frequency, gross hematuria, and suprapubic pain or tenderness were more discriminating symptoms. Fever was also a discriminating feature, although we consider patients with cystitis symptoms and fever to have a complicated UTI. (See "[Acute complicated urinary tract infection \(including pyelonephritis\) in adults](#)", section on 'Clinical manifestations'.)

Similarly, among debilitated patients, many generalized signs or symptoms, such as falls, change in functional status, and change in mental status, are frequently attributed to UTI, but growing evidence indicates that these are not reliable predictors of bacteriuria or cystitis. In one cohort study of nursing home residents, among clinical features that prompted evaluation for UTI (including change in gait or falls, change in functional status, fever or

chills), only acute dysuria, change in the character of urine (gross hematuria, change in color or odor), and change in mental status were associated with the presence of both pyuria and bacteriuria [39]. However, other studies that controlled for comorbidities have found no association between bacteriuria in nursing home patients and nonspecific mental status changes (such as increased restlessness, confusion, or aggression) [40]. Among those with bacteriuria, there also appears to be no association between these nonspecific mental status changes and urinary markers of inflammation (ie, interleukin-6) [41]. Furthermore, treatment of bacteriuria in patients with acute delirium or nonspecific symptoms is not associated with improvement in mental or functional status (but is associated with *Clostridioides* [formerly *Clostridium*] *difficile* infection) [42,43].

Although cloudy or smelly urine may be associated with bacteriuria (as demonstrated in nursing home residents [39]), there is no evidence of benefit to treating patients with only these complaints as having a UTI prior to onset of usual cystitis symptoms. Color and odor of urine are influenced by ingestion of certain foods, dehydration, and other noninfectious factors. Thus, increased fluid intake and careful observation are reasonable initial approaches to patients who complain of changes in odor or color of urine.

Fever, chills, rigors, and other signs of systemic illness are not compatible with a diagnosis of acute simple cystitis and raise the possibility of pyelonephritis or other complication of UTI. (See "[Acute complicated urinary tract infection \(including pyelonephritis\) in adults](#)".)

DIAGNOSTIC APPROACH

Clinical suspicion and evaluation — Acute simple cystitis should be suspected in women who have acute symptoms of dysuria, urinary frequency or urgency, and/or suprapubic pain, particularly in the absence of vaginal symptoms (eg, vaginal pruritus or discharge). The probability of cystitis is greater than 50 percent in women with any of these symptoms and greater than 90 percent in women who have dysuria and frequency without vaginal discharge or irritation [37].

Women should be asked about fevers/chills and flank pain. Physical examination is often not necessary for the diagnosis, but if performed, should include assessment for fever,

costovertebral angle tenderness, and abdominal tenderness. A pelvic examination is indicated if symptoms or signs suggesting vaginitis or urethritis are present. If fever ($>99.9^{\circ}\text{F}/37.7^{\circ}\text{C}$), other signs or symptoms of systemic illness (including chills, rigors, or marked fatigue or malaise beyond baseline), flank pain, or costovertebral angle tenderness are present, the patient should be evaluated and managed as potentially having complicated urinary tract infection (UTI), which is discussed in detail elsewhere. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults"](#).)

For most women with suspected acute simple cystitis, particularly those with classic symptoms, no additional testing is warranted to make the diagnosis.

However, in women who have clinical features that are suggestive, but not clearly diagnostic of cystitis (such as atypical urinary symptoms), urinalysis is a useful diagnostic tool, as the absence of pyuria on urinalysis suggests a diagnosis other than cystitis. Apart from the classic features listed above, features that should prompt urine testing include new or worsening urinary urgency, new incontinence, or gross hematuria. Chronic urinary nocturia, chronic incontinence, general malaise, and cloudy or malodorous urine are nonspecific findings that should not routinely prompt urine testing to evaluate for cystitis. We do not routinely test urine in elderly or debilitated patients with nonspecific changes in mental or functional status in the absence of focal urinary tract symptoms, and instead hydrate, carefully observe, and assess other potential contributing factors [44]. If fever is also present, evaluation for infection, including complicated UTI, is warranted (see ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults"](#)). The evaluation and diagnosis of UTI in elderly adults is further discussed elsewhere. (See ["Approach to infection in the older adult"](#), section on 'Urinary tract infection'.)

When indicated, urinalysis can be performed either by microscopy or by dipstick. (See ["Urinalysis"](#) below.)

Urine culture and susceptibility testing are also generally unnecessary in women with acute simple cystitis, but should be performed in patients who are at risk for infection with a resistant organism ([table 2](#)). We also check culture and susceptibility testing on patients with risk factors for more serious infection, such as those with underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes, regardless

of other risk factors for resistance. (See ['Determining the microbial etiology'](#) below.)

Pregnancy testing is appropriate in women of childbearing potential when the possibility of pregnancy cannot be reasonably excluded by history alone.

Blood testing is not warranted for patients with acute simple cystitis.

Urinalysis — Urinalysis (either by microscopy or by dipstick) for evaluation of pyuria is a valuable laboratory diagnostic test for UTI. It is not indicated in women with typical symptoms of acute simple cystitis (in whom the diagnosis can reliably be made on symptoms alone), but it can be helpful in cases in which the clinical presentation is not typical. Pyuria is present in almost all women with acute cystitis; its absence strongly suggests an alternative diagnosis [\[45,46\]](#).

- The most accurate method for assessing pyuria is to examine an unspun, voided midstream urine specimen under the microscope with a hemocytometer; an abnormal result is ≥ 10 leukocytes/microL [\[45\]](#). However, this laboratory test is usually not available to the clinician. The presence of hematuria is helpful since it is common in the setting of UTI but not in urethritis or vaginitis. However, hematuria is not a predictor for complicated infection and does not alter the approach to therapy. White blood cell casts in the urine, although rare, are indicative of upper tract infection rather than simple cystitis. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults", section on 'Diagnostic approach'.](#))
- Dipsticks are commercially available strips that detect the presence of leukocyte esterase (an enzyme released by leukocytes, reflecting pyuria) and nitrite (reflecting the presence of Enterobacteriaceae, which convert urinary nitrate to nitrite). The dipstick test is most accurate for predicting UTI when positive for either leukocyte esterase or nitrite, with a sensitivity of 75 percent and a specificity of 82 percent [\[37\]](#). However, results of the dipstick test provide little useful information when the clinical history is strongly suggestive of UTI, since even negative results for both tests do not reliably rule out infection in such cases.

Additional details on urine collection and testing (with microscopy for pyuria and dipstick) are found elsewhere. (See ["Sampling and evaluation of voided urine in the diagnosis of urinary](#)

[tract infection in adults".](#))

Determining the microbial etiology — The causative organisms and their antimicrobial susceptibility profiles are frequently predictable in women with acute simple cystitis, and thus routine cultures for such infections are often not necessary for management decisions. However, given the increasing prevalence of antimicrobial resistance among uropathogens, obtaining a urine culture prior to initiation of therapy is warranted in patients who have risk factors for antimicrobial resistance ([table 2](#)), as well as in patients at risk for more serious infection (eg, those with underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes mellitus).

If voided urine cultures are sent to the laboratory, the clinician should ask the laboratory to quantify *E. coli*, if it grows, to at least 10^3 colony-forming units/mL to improve specificity. Moreover, *E. coli* should not necessarily be considered a contaminant if it grows in mixed flora since almost any growth of *E. coli* in voided urine in a symptomatic patient reflects bladder growth [[10](#)]. Growth of organisms generally thought to be contaminants (such as lactobacilli, enterococci, Group B streptococci, and non-saprophyticus coagulase-negative staphylococci) may be considered causative when found in voided midstream urine at high counts and with pure growth (see '[Microbiology](#)' above). Issues related to interpretation of urine culture colony counts are discussed separately. (See "[Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults](#)", section on '[Definition of a positive culture](#)'.)

Diagnosis — The clinical diagnosis of cystitis is made in a patient who has classic signs and symptoms (ie, dysuria, urinary frequency, urgency, and/or suprapubic pain). For women who have atypical urinary symptoms, the diagnosis is supported by the presence of pyuria and bacteriuria on urinalysis and/or culture. (See '[Clinical suspicion and evaluation](#)' above.)

The clinical diagnosis of acute **simple** cystitis also excludes fever ($>99.9^{\circ}\text{F}/37.7^{\circ}\text{C}$), other signs or symptoms of systemic illness (including chills, rigors, or marked fatigue or malaise beyond baseline), flank pain, and costovertebral angle tenderness ([table 1](#)). The presence of any of these features suggests pyelonephritis or extension of the infection beyond the bladder, and we thus consider the patient to have an acute **complicated** UTI, which is discussed in detail elsewhere. We also have a lower threshold to consider patients with risk factors for more

serious infection as having acute complicated UTI, for example, if they have more subtle signs or symptoms of possible upper tract or systemic infection. Such risk factors include urologic abnormalities (eg, nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (eg, neutropenia or advanced HIV infection), or poorly controlled diabetes mellitus. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults"](#).)

Bacteriuria with or without pyuria in the absence of any symptom that could be attributable to a UTI is called asymptomatic bacteriuria and generally does not warrant treatment in nonpregnant patients who are not undergoing urologic procedures. (See ["Asymptomatic bacteriuria in adults"](#).)

The diagnosis of UTI in a patient with an indwelling urinary catheter is discussed in further detail elsewhere. (See ["Catheter-associated urinary tract infection in adults", section on 'Diagnosis'](#).)

DIFFERENTIAL DIAGNOSIS

Both infectious and noninfectious processes can cause symptoms of dysuria, frequency, urgency, suprapubic pain, and/or hematuria [9].

- Vaginitis – In women with dysuria, the presence of vaginal discharge or odor, pruritus, dyspareunia, and absence of urinary frequency or urgency should prompt consideration of vaginitis. Causes of vaginitis include yeast infection, trichomoniasis, and bacterial vaginosis. (See ["Approach to females with symptoms of vaginitis"](#).)
- Urethritis – Evaluation for urethritis is warranted in sexually active women with dysuria, particularly those with pyuria on urinalysis but no bacteriuria. Causes of urethritis in women include chlamydia, gonorrhea, trichomoniasis, *Candida* species, herpes simplex virus, and noninfectious irritants, such as a contraceptive gel. (See ["Clinical manifestations and diagnosis of Chlamydia trachomatis infections", section on 'Dysuria-pyuria syndrome due to urethritis'](#).)
- Painful bladder syndrome – This is a diagnosis of exclusion in women who have

ongoing discomfort related to the bladder with symptoms of dysuria, frequency, and/or urgency but no evidence of infection or other identifiable cause. (See ["Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis"](#).)

- Pelvic inflammatory disease – Lower abdominal or pelvic pain and fever are the most common clinical findings in patients with pelvic inflammatory disease (PID), although dysuria may also be present. The findings of mucopurulent endocervical discharge or cervical motion tenderness on pelvic examination are strongly suggestive of PID. (See ["Pelvic inflammatory disease: Clinical manifestations and diagnosis"](#).)

MANAGEMENT

Empiric antimicrobial selection — The selection of an antimicrobial regimen for acute simple cystitis ([table 1](#)) depends on the risk of infection with a multidrug-resistant (MDR) gram-negative organism ([algorithm 1](#)).

We generally consider patients to be higher risk for an MDR gram-negative organism if they have any of the following occurring in the prior three months:

- An MDR gram-negative urinary isolate (ie, nonsusceptible to at least one agent in three or more antimicrobial classes; this includes extended-spectrum beta-lactamase [ESBL]-producing isolates).
- Inpatient stay in a health care facility (eg, hospital, nursing home, long-term acute care facility).
- Use of a fluoroquinolone, [trimethoprim-sulfamethoxazole](#), or broad-spectrum beta-lactam (eg, third or later generation cephalosporin) [[47](#)].
- Travel to parts of the world with high rates of MDR organisms (eg, India, Israel, Spain, Mexico).

Women categorized as having acute uncomplicated cystitis according to the traditional definition would fall under the definition of acute simple cystitis that we use here and be managed as presented here. (See ['Terminology'](#) above.)

Low risk for resistance — For patients who do not have risk factors for an MDR gram-

negative infection ([table 2](#)), we typically choose one of the first-line antimicrobial regimens ([nitrofurantoin](#) monohydrate/macrocrystals, [trimethoprim-sulfamethoxazole](#), [fosfomycin](#), or [pivmecillinam](#)) ([algorithm 1](#)). (See '[First-line antimicrobial options](#)' below.)

For patients who have reasons to avoid all these options (either because of allergies or intolerances or a history of a urinary isolate resistant to these agents within the prior three months), we choose an alternative option. (See '[Alternative antimicrobial options](#)' below.)

First-line antimicrobial options — The preferred agents for empiric therapy of acute simple cystitis are [nitrofurantoin](#) monohydrate/macrocrystals, [trimethoprim-sulfamethoxazole](#), [fosfomycin](#), and, if available, [pivmecillinam](#) because of the favorable balance between efficacy and adverse effects (including the risk of selecting for resistant organisms) [1]. None of the first-line agents clearly outweighs the others in terms of the efficacy/adverse effects balance, with the exception that resistance is more likely with trimethoprim-sulfamethoxazole and that pivmecillinam (and possibly fosfomycin) is somewhat less effective; the optimal antimicrobial in one region may be different from that in another depending on resistance prevalence (see '[Resistance trends in E. coli](#)' above). Thus, the choice among them should be individualized based on patient circumstances (allergy, tolerability, expected adherence), local community resistance prevalence, availability, cost, and patient and provider threshold for failure. If the patient has taken one of the agents in the preceding three months, a different one should be selected.

If all these are appropriate options based on patient circumstances and prior urinary isolates, we suggest [nitrofurantoin](#) or [trimethoprim-sulfamethoxazole](#) rather than [fosfomycin](#) or [pivmecillinam](#). Because fosfomycin retains activity against many MDR isolates and overuse may result in increasing rates of resistance, we favor reserving it for suspected MDR infections or when other first-line agents cannot be used. Pivmecillinam is somewhat less effective but is commonly used in Europe because of a low risk of selection for resistance.

Details on dosing, expected efficacy, and additional reasons for avoidance are as follows:

- [Nitrofurantoin](#) monohydrate/macrocrystals (Macrobid) – Dosed at 100 mg orally twice daily for five days. Randomized trials suggest a 79 to 92 percent clinical cure rate with a

five- to seven-day regimen, with minimal resistance promotion [48-50]. Higher rates of failure occurred with shorter courses [51]. It has minimal propensity to select for resistant organisms. Nitrofurantoin should be avoided if there is suspicion for early pyelonephritis or if the creatinine clearance is <30 mL/minute. Observational studies have suggested that the agent is effective and safe with mild renal impairment, even in older women [52-55].

- [Trimethoprim-sulfamethoxazole](#) – Dosed as one double-strength tablet (160/800 mg) orally twice daily for three days. Randomized trials suggest a 79 to 100 percent clinical cure rate with a three- to seven-day regimen [48,56-58]. Empiric trimethoprim-sulfamethoxazole should be avoided if the regional prevalence of resistance is known to exceed 20 percent [29,30]. In some regions, [trimethoprim](#) (100 mg twice daily for three days) is used in place of trimethoprim-sulfamethoxazole and is considered equivalent [59].
- [Fosfomycin](#) – Dosed as 3 grams of powder mixed in water as a single oral dose. One randomized trial reported an early clinical cure rate of 91 percent and a bacterial cure rate similar to [nitrofurantoin](#) [60], and a meta-analysis demonstrated no difference in cure rates between fosfomycin and other agents, including fluoroquinolones, [trimethoprim-sulfamethoxazole](#), and nitrofurantoin [61]. However, in a subsequent open-label trial, a single dose of fosfomycin resulted in lower clinical (58 versus 70 percent) and microbiologic (63 versus 74 percent) success rates at 28 days compared with nitrofurantoin given three times daily for five days [62]. Lower than expected clinical success rates in both groups may be a result of the definition used in this study (complete resolution of UTI signs and symptoms rather than improvement of signs and symptoms, as used in other trials). It is not clear whether the open-label trial design influenced the findings [63]. Susceptibility testing for fosfomycin is not routinely available in most clinical laboratories. Fosfomycin should be avoided if there is suspicion for early pyelonephritis.
- [Pivmecillinam](#) – Doses used in studies range from 400 mg orally two or three times daily for three to seven days; we suggest a dose of 400 mg three times daily for three to five days. In one randomized trial of women with cystitis, the 400 mg three times daily dose given for three versus five days resulted in similarly high clinical (73 versus 76 percent)

and microbiologic success rates (87 versus 88 percent) [64]. Pivmecillinam is a penicillin with an extended gram-negative spectrum, is used only for treatment of urinary tract infection (UTI) and has minimal propensity to select for resistant organisms [65,66]. It is not available in the United States but is an agent of choice in many Nordic countries due to low resistance rates [67]. Pivmecillinam should be avoided if there is suspicion for early pyelonephritis.

These antimicrobial options and suggested treatment durations for acute simple cystitis are the same for any adult woman with acute simple cystitis, regardless of age. A systematic review of studies evaluating treatment of cystitis in community-dwelling adults ≥ 65 years of age concluded that the optimal regimens are the same as those recommended for younger adults and that shorter antimicrobial courses (three to six days) resulted in similar outcomes as longer ones (7 to 14 days) [68]. However, since these studies excluded women with urinary tract abnormalities, immunocompromising conditions, or poorly controlled diabetes mellitus, it is reasonable to use a longer duration of therapy (eg, 7 days) in women with such comorbidities.

If there is diagnostic uncertainty regarding cystitis versus early pyelonephritis, we treat the patient as having an acute complicated UTI (which includes pyelonephritis). In particular, the use of [nitrofurantoin](#), [fosfomycin](#), and [pivmecillinam](#) should be avoided in such cases because they do not achieve adequate renal tissue levels [1]. This is discussed in detail elsewhere. (See "[Acute complicated urinary tract infection \(including pyelonephritis\) in adults](#)", section on 'Management'.)

Alternative antimicrobial options — If any factors (such as allergies or concern for resistance) preclude use of the above first-line antimicrobials, oral beta-lactams (other than [pivmecillinam](#)) are appropriate options, and if beta-lactams cannot be used, a fluoroquinolone is reasonable ([algorithm 1](#)).

Acceptable beta-lactam agents include [amoxicillin-clavulanate](#) (500 mg twice daily), [cefpodoxime](#) (100 mg twice daily), [cefdinir](#) (300 mg twice daily), and [cefadroxil](#) (500 mg twice daily), each given for five to seven days [58,69,70]. A shorter course is not adequate; in one trial, cefpodoxime did not meet criteria for noninferiority to [ciprofloxacin](#) for clinical cure when each was given for three days [71]. Other beta-lactams, such as [cephalexin](#) (250 to 500

mg every six hours), are less well studied but may be acceptable. [Ampicillin](#) or [amoxicillin](#) should **not** be used for empiric treatment given the high prevalence of resistance to these agents [[16-19,59](#)]. In general, beta-lactams are second-line agents because they are less effective and have more potential adverse effects than other UTI antimicrobials [[59,70,72](#)].

If beta-lactams cannot be used (eg, because of severe allergy), [ciprofloxacin](#) (250 mg twice daily or 500 mg extended release daily) and [levofloxacin](#) (250 mg daily), each for three days, are reasonable alternative agents. Other less commonly used fluoroquinolones that are effective include [ofloxacin](#) and [norfloxacin](#). [Moxifloxacin](#) attains lower urinary levels than other fluoroquinolones and should not be used. Multiple randomized trials have demonstrated that fluoroquinolones are very effective for treatment of acute cystitis, and that fluoroquinolones are more effective than beta-lactams [[57,66,69,70,73-78](#)]. However, increasing rates of resistance mitigate the utility of the fluoroquinolone class. Furthermore, because of concerns about the adverse effects of fluoroquinolones, the risk-benefit balance for acute cystitis favors the use of fluoroquinolones only if other agents (including beta-lactams) cannot be used. When possible, fluoroquinolones should be reserved for more serious infections than acute simple cystitis [[79,80](#)]. If a fluoroquinolone is used, patients should be advised about the uncommon but potentially serious musculoskeletal and neurologic adverse effects. (See "[Fluoroquinolones](#)", [section on 'Benefits and risks of use'](#).)

If a patient has reasons not to use any of the first-line agents, beta-lactams, or fluoroquinolones, we obtain urine culture and susceptibility testing and select an antimicrobial based on those results (see "[Directed antimicrobial selection](#)" below). For acute simple cystitis, studies among women without comorbidities have suggested that deferring antimicrobial therapy until these results are available is a safe strategy [[81](#)]. Analgesics can be used for symptomatic therapy in the interim for women with mild to moderate symptoms (see "[Symptomatic therapy](#)" below). If there are concerns about deferring antimicrobials (eg, because of significant bladder symptoms), it is reasonable to treat empirically with an agent (eg, first-line option, beta-lactam, or fluoroquinolone) that was initially avoided because of concerns for possible resistance while awaiting culture results. Alternately, if there are concerns about potential treatment failure with oral agents in patients with risk factors for more serious infection (eg, an underlying urologic condition or immunocompromising condition), the patient can be treated with an initial intravenous agent, as in our approach to

complicated UTI. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults", section on 'Outpatients'.](#))

High risk for resistance — For patients who have risk factors for an MDR gram-negative infection ([table 2](#)), we first obtain urine culture and susceptibility testing ([algorithm 1](#)). For empiric treatment, oral options include [nitrofurantoin](#) monohydrate/macrocrystals (Macrobid, 100 mg orally twice daily for five days), [fosfomycin](#) (3 grams of powder mixed in water as a single dose), or, if available, [pivmecillinam](#) (400 mg orally three times daily for three to five days), unless the patient has a history of an isolate with documented resistance to these agents in the prior three months. If all these are appropriate options based on patient circumstances (allergies, intolerances, drug interactions) and prior urinary isolates, we suggest nitrofurantoin. We favor reserving the use of fosfomycin for documented MDR gram-negative infections or when nitrofurantoin is not an option, and pivmecillinam is not as effective. In the United States, resistance to all oral options is still uncommon among outpatients with *E. coli* cystitis.

Studies have suggested that [nitrofurantoin](#), [fosfomycin](#), and [pivmecillinam](#) still retain clinical activity against some MDR organisms, including ESBL-producing isolates [[35,72,82,83](#)]. As an example, in a case-control study including 113 patients with ESBL-producing *E. coli* UTIs, no resistance to fosfomycin was detected and clinical cure rates were high (93 percent) [[72](#)]. Some studies have evaluated a higher dose of fosfomycin (eg, 3 g once every 2 to 3 days for 3 doses) for infections due to MDR organisms, but there is no evidence that this has greater efficacy than single-dose therapy [[84,85](#)].

If none of these can be used because of resistance or other concerns, we defer antimicrobial therapy until a regimen can be selected based on results of culture and susceptibility testing (see ["Directed antimicrobial selection"](#) below). For acute simple cystitis, studies among women without comorbidities have suggested that deferring antimicrobial therapy until these results are available is a safe strategy [[81](#)]. Analgesics can be used for symptomatic therapy in the interim for women with mild to moderate symptoms (see ["Symptomatic therapy"](#) below). If there are concerns about deferring antimicrobials (eg, because of significant bladder symptoms), it is reasonable to treat empirically with an agent (eg, first-line option, beta-lactam, or fluoroquinolone) that was initially avoided because of concerns for possible resistance while awaiting culture results. Alternately, if there are concerns about

potential treatment failure with oral agents in patients with risk factors for more serious infection (eg, an underlying urologic condition or immunocompromising condition), the patient can be treated with an initial intravenous agent, as in our approach to complicated UTI. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults", section on 'Outpatients'.](#))

Directed antimicrobial selection — Acute simple cystitis in women is often treated empirically without culture and susceptibility testing. If such testing was performed (eg, because of risk for resistance or severe infection), those results can be used to inform regimen selection or adjustment. If susceptibility of the isolate allows, the approach to antimicrobial selection generally follows the same preferences as for empiric antimicrobial regimen selection, with [nitrofurantoin](#), [trimethoprim-sulfamethoxazole](#), [fosfomycin](#), and, if available, [pivmecillinam](#) as the preferred agents, followed by beta-lactams, followed by fluoroquinolones. The doses and durations for each option are detailed elsewhere. (See ["First-line antimicrobial options"](#) above and ["Alternative antimicrobial options"](#) above.)

If an *Enterococcus* or Group B *Streptococcus* grows as the only isolate on culture and is determined to be the cause of cystitis (see ["Determining the microbial etiology"](#) above), [amoxicillin](#) is usually the preferred agent, as long as the isolate is susceptible. (See ["Treatment of enterococcal infections", section on 'Urinary tract infection'](#) and ["Group B streptococcal infections in nonpregnant adults", section on 'Regimen selection'.](#))

Antimicrobial sparing strategies — Given that acute simple cystitis is associated with increasing antimicrobial resistance and has a low risk of progression to invasive disease in patients without risk factors for serious infection, antimicrobial sparing management strategies for some women with simple cystitis are of increasing interest (eg, anti-inflammatory drugs or delayed treatment), but warrant further study before they can be routinely employed [[81,86,87](#)].

Delaying antimicrobial therapy while awaiting urine culture results appears to be a reasonable approach in women without comorbidities if empiric therapy is complicated by resistance or drug intolerance. In a randomized trial of nonpregnant women <75 years of age with acute simple cystitis, symptom duration and severity were similar with immediate antimicrobial therapy compared with four other strategies, including delayed antimicrobial

therapy and antimicrobial therapy based on a symptom score, urinalysis findings, or urine culture results [81]. Although a large retrospective database analysis of patients ≥ 65 years of age with lower urinary tract infection suggested an association between delaying antimicrobial therapy and subsequent bloodstream infection within 60 days, multiple limitations of this study reduce confidence in the findings; these include potential misdiagnosis of cystitis, important and potentially confounding differences between groups, and failure to link the microbiology of the cystitis to bacteremia [88].

Substituting anti-inflammatory agents for antimicrobial therapy has also been evaluated but, pending additional data, cannot be recommended as an initial approach to management of symptomatic acute simple cystitis. In one trial of 241 women with acute simple cystitis without risk factors for complications, those randomly assigned to treatment with [ibuprofen](#) (400 mg three times daily for three days) had a higher mean symptom burden compared with those who received [fosfomycin](#) as a single 3 g dose [87]. Fewer women in the ibuprofen group received any antimicrobials compared with the fosfomycin group (35 versus 100 percent), but they were more likely to require additional therapy with antimicrobials in follow-up and had a higher rate of serious adverse events, including five cases of pyelonephritis (2 percent) compared with one case (0.4 percent) in the fosfomycin group. Similar findings were observed in a trial comparing [diclofenac](#) with [norfloxacin](#) [89].

Other interventions

Symptomatic therapy — Symptoms of acute simple cystitis should respond to antimicrobial therapy within 48 hours. In fact, dysuria is usually diminished within a few hours after the start of antimicrobial therapy [90]. In the interim, for some patients with severe dysuria, a urinary analgesic such as over-the-counter oral [phenazopyridine](#) three times daily as needed may be useful to relieve discomfort. A two-day course is usually sufficient to allow time for symptomatic response to antimicrobial therapy and minimize inflammation. Phenazopyridine should not be used chronically since it may mask clinical symptoms requiring clinical evaluation.

Patients with urologic abnormalities — In many cases, patients with underlying functional or anatomic urinary tract abnormalities (such as an indwelling catheter, urethral stent, neurogenic bladder, nephrolithiasis) have systemic symptoms (such as fever or

autonomic dysreflexia) in the setting of UTI and are thus managed as having a complicated UTI. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults", section on 'Management'.](#))

For those who appear to have only acute simple cystitis without upper tract or systemic symptoms, we believe that it is reasonable to cautiously treat them as outlined above. However, because these patients were not included in efficacy studies of the regimens we use for simple cystitis, we monitor them carefully for treatment failure (eg, persistent symptoms after initiation of empiric therapy) and follow initial urine cultures to ensure that the empirically chosen regimen was appropriate. Furthermore, since the antimicrobial durations listed above have not been well studied in patients with urologic dysfunction, a longer duration of therapy (eg, one to two weeks, depending on the agent chosen) is reasonable. It is also reasonable to have a lower threshold to treat such patients as having a complicated UTI (eg, for more subtle symptoms of pyelonephritis or systemic infection).

In addition, other treatment measures in addition to antimicrobial therapy may be warranted. These include more frequent intermittent catheterization, changing out an indwelling catheter prior to obtaining a urine culture (particularly if it has been in place for longer than one or two weeks), or urologic/urogynecologic consultation.

FOLLOW-UP

Follow-up urine cultures are not needed in patients with acute simple cystitis whose symptoms resolve on antimicrobials. For patients who had hematuria on initial presentation, a urinalysis should be repeated several weeks following antimicrobial therapy to evaluate for persistent hematuria. (See ["Etiology and evaluation of hematuria in adults", section on 'Overall approach to the evaluation'.](#))

Patients who have persistent symptoms after 48 to 72 hours of empiric antimicrobial therapy or have recurrent symptoms within a few weeks of treatment should have additional evaluation for other potential conditions that may be causing those symptoms and for factors that might be compromising clinical response. This includes urine culture and empiric treatment with another antimicrobial agent. Subsequent treatment should be tailored to the

susceptibility profile of the causative organism isolated (see ['Directed antimicrobial selection'](#) above). If symptoms persist in the setting of appropriate antimicrobial therapy, urologic assessment and radiographic imaging (generally with computed tomography) may be appropriate to evaluate for anatomic abnormalities that would interfere with response to antimicrobial treatment.

SOCIETY GUIDELINE LINKS

Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See ["Society guideline links: Urinary tract infections in adults"](#).)

INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

- Basics topic (see ["Patient education: Urinary tract infections in adults \(The Basics\)"](#))
 - Beyond the Basics topics (see ["Patient education: Urinary tract infections in adolescents and adults \(Beyond the Basics\)"](#) and ["Patient education: Kidney infection \(pyelonephritis\) \(Beyond the Basics\)"](#))
-

SUMMARY AND RECOMMENDATIONS

- We use the term acute simple cystitis to refer to an acute infection that is confined to the bladder in a nonpregnant individual ([table 1](#)). Such infections lack features that suggest infection extends beyond the bladder, such as fever ($>99.9^{\circ}\text{F}/37.7^{\circ}\text{C}$), other signs or symptoms of systemic illness (including chills, rigors, and marked fatigue or malaise beyond baseline), flank pain, and costovertebral angle tenderness. This definition is distinct from traditional categorizations of urinary tract infection (UTI) and is more focused on the clinical presentation and severity of illness.

Women categorized as having acute uncomplicated cystitis according to traditional definitions would fall under the definition of acute simple cystitis that we use here. (See ['Terminology'](#) above.)

- *Escherichia coli* is the most frequent microbial cause of cystitis, with occasional infections caused by other species of Enterobacteriaceae, such as *Klebsiella pneumoniae* and *Proteus mirabilis*, and other bacteria, such as *Staphylococcus saprophyticus*. The microbial spectrum of cystitis in patients with recent antimicrobial or other health care exposures may be broader and also include other gram-negative bacilli (eg, *Pseudomonas*), enterococci, and staphylococci. Increasing rates of resistance in uropathogens have been reported globally. Risk factors for UTI with resistant organisms include recent antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant (MDR) organisms are prevalent ([table 2](#)). (See ['Microbiology'](#) above.)
- The classic clinical manifestations of cystitis consist of dysuria, urinary frequency, urinary urgency, and suprapubic pain. Symptoms of cystitis can be difficult to assess in older or debilitated women, who can have a number of nonspecific urinary symptoms (such as chronic dysuria or urinary incontinence) that could mimic symptoms of cystitis. (See ['Clinical manifestations'](#) above.)
- For women with classic symptoms of cystitis, no additional testing is warranted to make the diagnosis. For women who have atypical urinary symptoms, the diagnosis is supported by the presence of pyuria and bacteriuria on urinalysis and/or culture.

Chronic nocturia, chronic incontinence, general malaise, and cloudy or malodorous urine are nonspecific findings that should not routinely prompt urine testing to evaluate for cystitis. (See '[Clinical suspicion and evaluation](#)' above and '[Diagnosis](#)' above.)

The selection of an antimicrobial regimen for acute simple cystitis depends on the likelihood of infection with an MDR gram-negative isolate ([algorithm 1](#)). Prior to initiation of therapy, urine culture and susceptibility testing are warranted for patients who have risk factors for antimicrobial resistance ([table 2](#)) or for more serious infection (eg, those with underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes mellitus). (See '[Empiric antimicrobial selection](#)' above.)

- For patients who do not have risk factors for an MDR gram-negative infection ([table 2](#)), the first-line antimicrobial agents include [nitrofurantoin](#) monohydrate/macrocrystals (Macrobid, 100 mg twice daily for five days), [trimethoprim-sulfamethoxazole](#) (one double-strength tablet [160/800 mg] twice daily for three days), [fosfomycin](#) (3 grams of powder mixed in water as a single dose), or [pivmecillinam](#) (400 mg twice daily for five to seven days). If all these are appropriate options based on patient circumstances, local resistance rates, and prior urinary isolates, we suggest nitrofurantoin or trimethoprim-sulfamethoxazole rather than fosfomycin or pivmecillinam (**Grade 2C**). (See '[First-line antimicrobial options](#)' above.)
- Oral beta-lactams are appropriate alternative options for those who cannot use any of the first-line antimicrobials. If beta-lactams cannot be used, a fluoroquinolone is reasonable; however, these should be reserved for more serious infections than acute simple cystitis, if possible, because of concerns of adverse effects. (See '[Alternative antimicrobial options](#)' above.)
- For patients who have risk factors for an MDR gram-negative infection ([table 2](#)), oral options include [nitrofurantoin](#) monohydrate/macrocrystals (Macrobid, 100 mg orally twice daily for five days), [fosfomycin](#) (3 grams of powder mixed in water as a single dose), or, if available, [pivmecillinam](#) (400 mg orally three times daily for three

to five days) unless the patient has a history of an isolate with documented resistance to these agents in the prior three months. If all these are appropriate options based on patient circumstances, local resistance rates, and prior urinary isolates, we suggest nitrofurantoin ([Grade 2C](#)). Culture and susceptibility results should be used to guide directed therapy. (See ['High risk for resistance'](#) above.)

- If none of these options are appropriate because of resistance or other concerns, we defer antimicrobial therapy until a regimen can be selected based on results of culture and susceptibility testing. For acute simple cystitis, studies among women without comorbidities have suggested that deferring antimicrobial therapy until these results are available is a safe strategy. However, if there is concern about deferring antimicrobial therapy (eg, because of bothersome symptoms or risk factors for more serious infection), options include using one of the oral regimens for simple cystitis that was not chosen because of the possibility of resistance or using an initial dose of a parenteral agent, as used in acute complicated UTI. (See ["Acute complicated urinary tract infection \(including pyelonephritis\) in adults", section on 'Outpatients'.](#))
- Patients who have acute simple cystitis in the setting of underlying functional or anatomic urinary tract abnormalities (such as an indwelling catheter, urethral stent, neurogenic bladder, history of nephrolithiasis) may warrant more frequent catheterization, changing out an indwelling catheter, or urologic/urogynecologic consultation. Additionally, a longer duration of antimicrobial therapy is appropriate, since shorter durations have not been well studied in such patients. (See ['Patients with urologic abnormalities'](#) above.)
- Patients who have persistent symptoms after 48 to 72 hours of empiric antimicrobial therapy or have recurrent symptoms within a few weeks of treatment should have urine submitted for culture and susceptibility testing. If symptoms persist in the setting of appropriate antimicrobial therapy, radiographic imaging to evaluate for anatomic abnormalities is appropriate. (See ['Follow-up'](#) above.)

REFERENCES

1. [Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the](#)

- [treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.](#)
2. [Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28:1.](#)
 3. [Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011; :1.](#)
 4. [Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335:468.](#)
 5. [Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142:20.](#)
 6. [Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.](#)
 7. [Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29:113.](#)
 8. [Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366:1028.](#)
 9. [Gupta K, Trautner B. In the clinic. Urinary tract infection. Ann Intern Med 2012; 156:ITC3.](#)
 10. [Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 2013; 369:1883.](#)
 11. [Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Emerg Med Int 2013; 2013:258517.](#)
 12. [Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38:1148.](#)
 13. [Walker E, Lyman A, Gupta K, et al. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis 2016; 63:960.](#)
 14. [Smithson A, Chico C, Ramos J, et al. Prevalence and risk factors for quinolone resistance](#)

- [among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 2012; 31:423.](#)
15. [Linszenmeyer K, Strymish J, Gupta K. Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections. Antimicrob Agents Chemother 2015; 59:7593.](#)
 16. [Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22 Suppl 2:49.](#)
 17. [Kahlmeter G, ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003; 51:69.](#)
 18. [Naber KG, Schito G, Botto H, et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis \(ARESC\): implications for empiric therapy. Eur Urol 2008; 54:1164.](#)
 19. [Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance \(NAUTICA\). Int J Antimicrob Agents 2006; 27:468.](#)
 20. [Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56:2181.](#)
 21. [Swami SK, Liesinger JT, Shah N, et al. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin Proc 2012; 87:753.](#)
 22. [Gupta K, Hooton TM, Miller L, Uncomplicated UTI IDSA Guideline Committee. Managing uncomplicated urinary tract infection--making sense out of resistance data. Clin Infect Dis 2011; 53:1041.](#)
 23. [Richards DA, Toop LJ, Chambers ST, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J 2002; 115:12.](#)
 24. [Ti TY, Kumarasinghe G, Taylor MB, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient](#)

- [specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis 2003; 22:242.](#)
25. [Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002; 34:1061.](#)
 26. [Metlay JP, Strom BL, Asch DA. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. J Antimicrob Chemother 2003; 51:963.](#)
 27. [Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob Agents Chemother 2008; 52:846.](#)
 28. [Olson RP, Harrell LJ, Kaye KS. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother 2009; 53:1285.](#)
 29. [Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003; 17:243.](#)
 30. [Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole \(TMP-SMX\) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34:1165.](#)
 31. [Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004; 79:1048.](#)
 32. [Talan DA, Krishnadasan A, Abrahamian FM, et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008; 47:1150.](#)
 33. [Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4:S341.](#)
 34. [Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.](#)

[Int J Antimicrob Agents 2009; 34:407.](#)

35. [Ho PL, Yip KS, Chow KH, et al. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis 2010; 66:87.](#)
36. [Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin Infect Dis 2013; 57:1266.](#)
37. [Bent S, Nallamotheu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002; 287:2701.](#)
38. [Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA 2014; 311:844.](#)
39. [Juthani-Mehta M, Quagliarello V, Perrelli E, et al. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc 2009; 57:963.](#)
40. [Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract 2011; 12:36.](#)
41. [Sundvall PD, Elm M, Ulleryd P, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr 2014; 14:88.](#)
42. [Dasgupta M, Brymer C, Elsayed S. Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study. Arch Gerontol Geriatr 2017; 72:127.](#)
43. [Potts L, Cross S, MacLennan WJ, Watt B. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr 1996; 23:153.](#)
44. [Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc 2014; 15:133.](#)
45. [Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med 1983; 75:53.](#)
46. [Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004; 38:1150.](#)
47. [Brosh-Nissimov T, Navon-Venezia S, Keller N, Amit S. Risk analysis of antimicrobial](#)

- [resistance in outpatient urinary tract infections of young healthy adults. J Antimicrob Chemother 2019; 74:499.](#)
48. [Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167:2207.](#)
 49. [McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc 2011; 86:480.](#)
 50. [Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother 2015; 70:2456.](#)
 51. [Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995; 273:41.](#)
 52. [Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ 2015; 187:648.](#)
 53. [Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013; 47:106.](#)
 54. [By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015; 63:2227.](#)
 55. [Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc 2016; 64:798.](#)
 56. [Arredondo-García JL, Figueroa-Damián R, Rosas A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004; 54:840.](#)
 57. [Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999; 43](#)

Suppl A:67.

58. [Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003; 47:897.](#)
59. [Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America \(IDSA\). Clin Infect Dis 1999; 29:745.](#)
60. [Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21:1864.](#)
61. [Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1862.](#)
62. [Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. JAMA 2018; doi:10.1001/jama.2018.3627.](#)
63. [Datta R, Juthani-Mehta M. Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis. JAMA 2018; 319:1771.](#)
64. [Jansåker F, Thønnings S, Hertz FB, et al. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine 2019; 12:62.](#)
65. [Ferry SA, Holm SE, Stenlund H, et al. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 2007; 25:49.](#)
66. [Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002; 34:487.](#)
67. [Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl 2:73.](#)
68. [Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic](#)

- [lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2008; :CD001535.](#)
69. [Auguer F, Cordon F, Gorina E, et al. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clin Microbiol Infect 2002; 8:50.](#)
 70. [Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293:949.](#)
 71. [Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012; 307:583.](#)
 72. [Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli*. Arch Intern Med 2008; 168:1897.](#)
 73. [Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother 1998; 42:2262.](#)
 74. [Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002; 59:334.](#)
 75. [Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005; 49:4137.](#)
 76. [Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002; 24:2088.](#)
 77. [Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004; 170:469.](#)
 78. [Zalmanovici Trestioreanu A, Green H, Paul M, et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010;](#)

[:CD007182.](#)

79. [Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75.](#)
80. US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: <http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm> (Accessed on May 26, 2016).
81. [Little P, Moore MV, Turner S, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010; 340:c199.](#)
82. [Qiao LD, Chen S, Yang Y, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3:e004152.](#)
83. [Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014; 69:769.](#)
84. [Loethen AA, Kerstenetzky L, Descourouez JL, et al. Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population. Pharmacotherapy 2017; 37:599.](#)
85. [Seroy JT, Grim SA, Reid GE, et al. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. J Antimicrob Chemother 2016; 71:2563.](#)
86. [Bleidorn J, Gágyor I, Kochen MM, et al. Symptomatic treatment \(ibuprofen\) or antibiotics \(ciprofloxacin\) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial. BMC Med 2010; 8:30.](#)
87. [Gágyor I, Bleidorn J, Kochen MM, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351:h6544.](#)
88. [Gharbi M, Drysdale JH, Lishman H, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ 2019; 364:l525.](#)
89. [Kronenberg A, Bütikofer L, Odutayo A, et al. Symptomatic treatment of uncomplicated](#)

[lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359:j4784.](#)

90. [Klimberg I, Shockey G, Ellison H, et al. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr Med Res Opin 2005; 21:1241.](#)

This generalized information is a limited summary of diagnosis, treatment, and/or medication information. It is not meant to be comprehensive and should be used as a tool to help the user understand and/or assess potential diagnostic and treatment options. It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances. Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications. This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. The use of this information is governed by the Terms of Use, available at <https://www.wolterskluwer.com/en/know/clinical-effectiveness-terms> ©2022 UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.

Topic 8063 Version 60.0

Contributor Disclosures

Thomas M Hooton, MD Equity Ownership/Stock Options: Fimbrion Therapeutics [UTI prevention]; Sequoia Vaccines [UTI prevention]. Consultant/Advisory Boards: Danone [UTI]; Ocean Spray [UTI]; Utility Therapeutics [UTI]; Sequoia Vaccines, Inc [UTI]. All of the relevant financial relationships listed have been mitigated. **Kalpna Gupta, MD, MPH** Equity Ownership/Stock Options: First Light Diagnostics [Rapid detection and antimicrobial testing of infections]. Grant/Research/Clinical Trial Support: Pfizer [Staphylococcus aureus post-surgical infections]. Consultant/Advisory Boards: Paratek Pharmaceuticals [UTI]; Nabriva [UTI]; Shionogi [UTI]; First Light Diagnostics [UTI]; Qiagen [UTI]; Glaxo-Smith Kline [UTI]; Utility Therapeutics [UTI]; Spero Therapeutics [UTI]. All of the relevant financial relationships listed have been mitigated. **Stephen B Calderwood, MD** Consultant/Advisory Boards: Day Zero Diagnostics [Whole genome sequencing for microbial identification and determination of antimicrobial susceptibility]. All of

the relevant financial relationships listed have been mitigated. **Allyson Bloom, MD** No relevant financial relationship(s) with ineligible companies to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy](#)

